Future large-scale prospective studies should focus on the optimal timing of P2Y12 inhibitor administration, comparing prior use to initiation at the time of infection diagnosis, and evaluating the efficacy and safety profiles of different P2Y12 inhibitors across various age groups. The gene discussed is P2RY12; the disease is infection.